Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
2.
J Med Chem ; 57(17): 7293-316, 2014 Sep 11.
Artigo em Inglês | MEDLINE | ID: mdl-25075638

RESUMO

In the search of a potential backup for clopidogrel, we have initiated a HTS campaign designed to identify novel reversible P2Y12 antagonists. Starting from a hit with low micromolar binding activity, we report here the main steps of the optimization process leading to the identification of the preclinical candidate SAR216471. It is a potent, highly selective, and reversible P2Y12 receptor antagonist and by far the most potent inhibitor of ADP-induced platelet aggregation among the P2Y12 antagonists described in the literature. SAR216471 displays potent in vivo antiplatelet and antithrombotic activities and has the potential to differentiate from other antiplatelet agents.


Assuntos
Indóis/farmacologia , Inibidores da Agregação Plaquetária/farmacologia , Agregação Plaquetária/efeitos dos fármacos , Antagonistas do Receptor Purinérgico P2/farmacologia , Piridazinas/farmacologia , Receptores Purinérgicos P2Y12/metabolismo , Síndrome Coronariana Aguda/prevenção & controle , Difosfato de Adenosina/farmacologia , Administração Oral , Animais , Ligação Competitiva , Células CHO , Cricetinae , Cricetulus , Humanos , Indóis/síntese química , Indóis/metabolismo , Injeções Intravenosas , Masculino , Modelos Químicos , Estrutura Molecular , Inibidores da Agregação Plaquetária/síntese química , Inibidores da Agregação Plaquetária/metabolismo , Antagonistas do Receptor Purinérgico P2/síntese química , Antagonistas do Receptor Purinérgico P2/metabolismo , Piridazinas/síntese química , Piridazinas/metabolismo , Ratos , Ratos Sprague-Dawley , Receptores Purinérgicos P2Y12/genética , Trombose/prevenção & controle
3.
J Med Chem ; 56(23): 9441-56, 2013 Dec 12.
Artigo em Inglês | MEDLINE | ID: mdl-24175584

RESUMO

Compound 15 (SAR107375), a novel potent dual thrombin and factor Xa inhibitor resulted from a rational optimization process. Starting from compound 14, with low factor Xa and modest anti-thrombin inhibitory activities (IC50's of 3.5 and 0.39 µM, respectively), both activities were considerably improved, notably through the incorporation of a neutral chlorothiophene P1 fragment and tuning of P2 and P3-P4 fragments. Final optimization of metabolic stability with microsomes led to the identification of 15, which displays strong activity in vitro vs factor Xa and thrombin (with Ki's of 1 and 8 nM, respectively). In addition 15 presents good selectivity versus related serine proteases (roughly 300-fold), including trypsin (1000-fold), and is very active (0.39 µM) in the thrombin generation time (TGT) coagulation assay in human platelet rich plasma (PRP). Potent in vivo activity in a rat model of venous thrombosis following iv and, more importantly, po administration was also observed (ED50 of 0.07 and 2.8 mg/kg, respectively). Bleeding liability was reduced in the rat wire coil model, more relevant to arterial thrombosis, with 15 (blood loss increase of 2-fold relative to the ED80 value) compared to rivaroxaban 2 and dabigatran etexilate 1a.


Assuntos
Anticoagulantes/síntese química , Inibidores do Fator Xa , Fibrinolíticos/síntese química , Piperazinas/síntese química , Sulfonamidas/síntese química , Trombina/antagonistas & inibidores , Animais , Anticoagulantes/farmacologia , Cristalografia por Raios X , Desenho de Fármacos , Fibrinolíticos/farmacologia , Humanos , Piperazinas/farmacologia , Piperazinas/uso terapêutico , Ratos , Sulfonamidas/farmacologia , Sulfonamidas/uso terapêutico , Trombose Venosa/tratamento farmacológico
4.
J Org Chem ; 71(4): 1449-57, 2006 Feb 17.
Artigo em Inglês | MEDLINE | ID: mdl-16468793

RESUMO

We describe a general synthetic strategy for the preparation of a series of macrocyclic chiral manganese(III) salen complexes. The developed reaction pathway allows the modulation of the different key groups, namely, the chiral diimine, the bulky substituents in positions 3 and 3', and the linker used in the macrocyclization of the Schiff base. The different complexes presented here illustrate these readily available structural variations. The catalytic properties of the catalysts (5 mol %) were improved for the asymmetric epoxidation of 2,2'-dimethylchromene with NaOCl or H2O2 as oxygen atom donor. A large range of enantiomeric excesses was obtained (ee values from 30% to 96%), depending on the features and the stability of the complexes. The most efficient catalyst, in terms of stereoinduction (ee value = 96%), contains a diiminocyclohexyl moiety, ethyl groups in positions 3 and 3', and a short polyether junction arm.


Assuntos
Catálise , Compostos de Epóxi/síntese química , Bases de Schiff/síntese química , Reagentes de Ligações Cruzadas/química , Ciclização , Etilenodiaminas , Iminas/química , Compostos Macrocíclicos/síntese química , Manganês/química , Estereoisomerismo , Relação Estrutura-Atividade
5.
J Am Chem Soc ; 126(25): 7764-5, 2004 Jun 30.
Artigo em Inglês | MEDLINE | ID: mdl-15212509

RESUMO

The tetramine ligand 1 hexasubstituted by very long alkyl chains (C18H37) exhibits an exceptionally large temperature-dependent solubility in 1,4-dioxane, its solubility increasing ca. approximately 104-fold between 23 and 50 degrees C. The preformed copper(I) complex CuBr/1 was shown to catalyze the atom transfer radical polymerization of methyl methacrylate with good control of the molar masses and polydispersities. Due to the thermoresponsive character of CuBr/1 polymerizations were carried out in homogeneous conditions while lowering the temperature to 10 degrees C led to the precipitation of the catalyst. Catalyst recovery was achieved with high yield ( approximately 95%) by a simple filtration under noninert atmosphere. Very low residual copper contamination ( approximately 200 ppm) was measured in the final polymer. The catalyst was recycled two times without significant loss of activity.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA